press center press release

Exiqon A/S Chief Executive Officer and Chief Financial Officer to Ring The NASDAQ Stock Market Closing Bell

Published

ADVISORY, Sept. 4, 2009 (GLOBE NEWSWIRE) --

What: Exiqon A/S will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, representatives of Exiqon A/S will preside over the NASDAQ Closing Bell. Who: -- Lars Kongsbak, Chief Executive Offer -- Hans Henrik Chrois Christensen, Chief Financial Officer Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Tuesday, September 8th, 2009 at 3:45 p.m. to 4:00 p.m. ET Contacts: Hans Henrik Chrois Christensen +45 456 50953 or +45 409 02131 (cell) hhc@exiqon.com Richard L. Anderson (212) 681-1700 ext. 115 (office) (718) 986-1596 (mobile) randerson@torrenzano.com NASDAQ MarketSite: Robert Madden (646) 441-5045 Robert.Madden@NASDAQOMX.com

Feed Information:

The Closing Bell is available from 3:50 p.m. to 4:05 p.m. on AMC-3/C-3 (ul 5985V; dl 3760H). The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Robert Madden at (646) 441-5045.

Radio Feed:

An audio transmission of the Closing Bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a high-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Exiqon A/S:

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: Sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyze the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqon's new molecular diagnostic products are based on the LNA(TM) technology that enables testing on fixed tissue. Launch of the first molecular diagnostic product was announced in December 2008. A number of new products will follow in the years ahead. Using the LNA(TM) technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development of various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 170 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

About NASDAQ OMX:

The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with over 3,700 listed companies. NASDAQ OMX Group offers multiple capital raising solutions to companies around the globe, including its U.S. listings market; NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North; and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and ETFs. NASDAQ OMX Group technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX Group exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com.

NDAQA

In This Story

NDAQ

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more